BIOV PapilocareBeen taking a look at the numbers for BIOV and Papilocare potenital. Reading from prior PR's they are looking to get FDA approval as a device hopefully this year (same as in the EU, where it is approved and being marketed, which increases liklihood of US device approval). Per the recent company presentation at GCFF, this could be a $30M-$50M product for BIOV. But...once launched as a device, no doubt they will look at new formulations/indications etc. and seek FDA approval for a follow-on "Papilocare+" as a therapeutic----this will command much higher price and revenue. $150M-$300M is realistic. With this,Covid-t and the EU ovarian cancer clinical study, 9 or so months from now this I think will be flying.